Fig. 3
From: Enhanced bacterial cancer therapy delivering therapeutic RNA interference of c-Myc
Modified SL7207 strains are well tolerated in vivo. Analysis of mice 7 days after IP administration of PBS vehicle (Apc+/+PBS) or 1 × 106 CFU SL7207/c-Myc. (A) Weight change data indicating no significant impact on weight gain of SL7207/c-Myc (N > 3). (B) PCR analysis of faecal DNA from mice administered SL7207/c-Myc demonstrating clearance of bacteria (Left panel: faecal DNA, Right panel: SL7207, bacteria and water controls). ELISA quantification of serum (C) and flow cytometry staining intensity of PBMCs (D) for Ccl2 indicating a significant increase in the presence of SL7207/c-Myc (t-test pairwise comparisons; *P < 0.01). (E-G) Quantification of cells in the crypt undergoing apoptosis (E), mitosis (F) and total crypt cell numbers (G)